Tofacitinib ameliorates skin inflammation in a patient with severe autosomal recessive congenital ichthyosis
Clinical and Experimental Dermatology · 2024-07-19 · 49 (8) · 887-892
DOI: 10.1093/ced/llae080 ↗At a glance
Fallbericht in Clinical and Experimental Dermatology, published online on 2024-03-12. Written by Yu-Chen Lin and 6 co-authors. Institution: Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Major MEDLINE topics: Pyrimidines, Piperidines. Cited 6 times so far (Crossref); 10 references. Funded by: International Center for Wound Repair, Regeneration at National Cheng Kung University, National Cheng Kung University Hospital.
Abstract (original language)
Autosomal recessive congenital ichthyosis (ARCI) is a genetically heterogeneous disorder with aberrant skin scaling and increased transepidermal water loss (TEWL). Current treatments for ARCI are limited and suboptimal. We present the case of a 27-year-old man with ARCI resulting from a homozygous missense variant in TGM1. RNA-sequencing of lesional skin revealed aberrant Janus kinase–signal transducer and activator of transcription signalling, providing a rationale for innovative treatment with a Janus kinase inhibitor. We prescribed oral tofacitinib (11 mg daily) for 26 weeks. Rapid improvements in erythema and fissuring occurred within the first month. Sustained reductions in 5-D itch scale and Dermatology Life Quality Index scores were also observed. TEWL decreased for the first 10 weeks but increased thereafter. Tofacitinib downregulated inflammatory genes and pathways, while enhancing skin barrier markers. Moreover, transglutaminase 1 distribution was normalized although enzymatic activity remained deficient. This study suggests that oral tofacitinib may be a useful therapy to consider for patients with ARCI.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- International Center for Wound Repair and Regeneration, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Cellular Biochemistry Laboratory, Graduate School of Pharmaceutical Sciences, Nagoya University, Nagoya, Japan.
- Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
- St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, UK.
ORCID profiles: Masashi Akiyama, John A McGrath, Chao-Kai Hsu
Funding
- International Center for Wound Repair
- Regeneration at National Cheng Kung University
- National Cheng Kung University Hospital
Cite
APA
Lin, Y. C., Hong, Y. K., Aala, W. J. F., Hitomi, K., Akiyama, M., McGrath, J. A., & Hsu, C. K. (2024). Tofacitinib ameliorates skin inflammation in a patient with severe autosomal recessive congenital ichthyosis. Clinical and Experimental Dermatology, 49(8), 887-892. https://doi.org/10.1093/ced/llae080
Vancouver
Lin YC, Hong YK, Aala WJF, Hitomi K, Akiyama M, McGrath JA, et al. Tofacitinib ameliorates skin inflammation in a patient with severe autosomal recessive congenital ichthyosis. Clinical and Experimental Dermatology. 2024;49(8):887-892. doi:10.1093/ced/llae080
BibTeX
@article{Lin2024,
author = {Lin, Yu-Chen and Hong, Yi-Kai and Aala, Wilson Jr F and Hitomi, Kiyotaka and Akiyama, Masashi and McGrath, John A and Hsu, Chao-Kai},
title = {Tofacitinib ameliorates skin inflammation in a patient with severe autosomal recessive congenital ichthyosis},
journal = {Clinical and Experimental Dermatology},
year = {2024},
volume = {49},
number = {8},
pages = {887--892},
doi = {10.1093/ced/llae080}
}
EUVIMED